Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P990081/S058

PATHWAY anti-HER-2/neu (4B5) Rabbit Monoclonal Primary Antibody

Ventana Medical Systems, Inc. · Decision date May 15, 2026

FDA DECISIONP990081/S058

What did the FDA approve?

FDA records P990081/S058 as a supplement to PMA P990081, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated May 15, 2026.

FDA approval order statement

Approval to include the PATHWAY anti-HER-2/neu (4B5) Rabbit Monoclonal Primary Antibody (PATHWAY anti-HER2 (4B5) antibody) as a companion diagnostic indication for the detection of HER2 antigen in patients with breast cancer who may benefit from treatment with ENHERTU (fam-trastuzumab deruxtecan-nxki).
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track
Clinical specialty
Pathology
Decision date
May 15, 2026
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record

Regulatory record facts

Identifier
P990081/S058
Regulatory pathway
PMA supplement
Product code
MVC
Decision code
APPR
Decision date
May 15, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: SYSTEM, TEST, HER-2/NEU, IHC.

Product code
MVC
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P990081/S058 received

    Application receipt date recorded by FDA.

  2. P990081/S059 · Related supplement

    PATHWAY anti- HER-2/neu (4B5) Rabbit Monoclonal Primary Antibody

  3. P990081/S058 · FDA decision

    Normal 180 Day Track

  4. P990081/S060 · Related supplement

    PATHWAY anti-HER-2/neu (4B5) Rabbit Monoclonal Primary Antibody

Timeline entries are records held by MedtechLedger for P990081. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P990081

Product / regulatory recordCompanyPathwayDecision dateSource
Ventana Medical Systems, Inc.PMA supplementDec 15, 2025FDA
Ventana Medical Systems, Inc.PMA supplementAug 25, 2026FDA

Explore the linked device profile

Other records with product code MVC

Product / regulatory recordCompanyPathwayDecision dateSource
HercepTestP980018/S027
Agilent Technologies Singapore (International) Pte , Ltd.PMA supplementSep 21, 2026FDA
Leica BiosystemsPMA supplementJun 4, 2026FDA
HercepTestP980018/S026
Agilent Technologies Singapore (International) Pte , Ltd.PMA supplementJan 28, 2026FDA
Agilent Technologies Singapore (International) Pte , Ltd.PMA approvalSep 25, 1998FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Ventana Medical Systems, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
1910 E. Innovation Park Dr., Tucson, AZ, 85755

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records